Expert Financial Analysis and Reporting

I am a little sad to see Antares sell out to Halozyme. I thought that the rubber was just starting to meet the road and that it was too early to consider selling out although this was always the likely long term outcome. Oh well, maybe management knows or fears something that I am not […]

Importance of Makena SC to AMAG? AMAG is engaged in a high stakes clinical development program in which it is endeavoring to gain approval of a subcutaneous dosage form of its key drug Makena. Management has guided that sales of Makena reached $333 to $336 million in 2016 (about 63% of total sales) and issued […]

Overview and Investment Opinion In my opinion, Antares is substantially undervalued. My price target is $6 60 $8 in 2018 and the thinking behind this was explained in my April 22 report An Outstanding Product Pipeline Promises Dramatic Growth Through 2022 Antares: An Outstanding Product Pipeline Promises Dramatic Growth Through 2022 (ATRS, Buy, $0.92) The stock […]

SmithOnStocks Mailbox About the Mailbox: My mailbox comments are brief articles on stocks in which I am involved. These can come from recent events or from subscribers’ questions. They are meant to address specific issues about these stocks and are not full and balanced reports. Please refer to the Reports section of my website for […]

SmithOnStocks Mailbox April 28, 2015 A Quick Take on Recent Events If you have a question for the mailbox, contact me. Purpose of this Note I have written extensively on Antares, Agenus, Cytokinetics and Discovery Laboratories. I have Buys on Antares, Agenus and Cytokinetics. I have a Hold on Discovery (what a troubled history), but […]

Overview I tuned in to the Antares presentation at the Piper Jaffrey conference on December 2, 2014 to listen to what the new CEO Eamonn Hobbs emphasized to investors in a short 15 minute presentation. He spent a lot of the time talking about Quick Shot Testosterone (QST), the new once a week subcutaneous injectable […]

The FDA does not appear to be concerned about cardiovascular risk with testosterone replacement products so this is a major positive. The FDA is asking the panel to consider if these products are used too much in unapproved indications. The testosterone replacement market has shrunk significantly in 2014 due to the cardiovascular safety issue. There […]

Investors Are Concerned About Rasuvo’s Impact on Otrexup Investors have been concerned about the potential effect on Otrexup if the private company Medac gains approval for Rasuvo. Both products are device drug combinations that use highly engineered and proprietary auto injectors to administer methotrexate as a sub-cutaneous injection. These products were both developed under the […]

This is a follow-up on Paul Wotton’s decision to leave his position as CEO of Antares (ATRS) to become CEO of Advanced Cell Technology (ACTC). In an 8-K filing, Antares said that Mr. Wotton’s resignation was not because of any disagreement with Antares on any matter relating to operations, policies or practices. I have heard […]

The resignation of Paul Wotton as CEO of Antares came as a surprise to me and I think most other investors. He has left to become chief executive officer of a development stage biotechnology company and has also resigned from the Board of Directors. There must have been some foreknowledge of and planning for his […]